Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8233450 | 1.00 | MAPT (0.39) | MAPTHTTTDP1RECQLLMNA | |
| SCHEMBL8231746 | 0.81 | HTT (0.41) | MAPTHTTTDP1RECQLLMNA | |
| SCHEMBL8231748 | 0.81 | HTT (0.41) | MAPTHTTTDP1RECQLLMNA | |
| SCHEMBL3756939 | 0.77 | HTT (0.39) | MAPTHTTTDP1RECQLLMNA | |
| SCHEMBL3756943 | 0.77 | HTT (0.39) | MAPTHTTTDP1RECQLLMNA | |
| SCHEMBL8230261 | 0.75 | ADORA2A (0.36) | HTTCYP2C19ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL28694360 | 0.73 | ADORA2A (0.44) | TDP1POLB | |
| SCHEMBL27890560 | 0.71 | ADORA2A (0.35) | KMT2A | |
| SCHEMBL3757896 | 0.70 | MAPT (0.33) | MAPTHTTTDP1RECQLLMNA | |
| SCHEMBL3757901 | 0.70 | MAPT (0.33) | MAPTHTTTDP1RECQLLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49556-E1 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-06-20 | — | — | US | claimed |
| US-8501758-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-08-06 | — | — | US | claimed |
| EP-2470526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-07-04 | — | — | EP | claimed |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-15 | — | — | US | claimed |
| WO-2011025927-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | WO | claimed |
| US-RE49556-E1 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230116233-A1 | Compounds And Compositions As Protein Kinase Inhibitors | ARRAY BIOPHARMA INC (US) | 2023-04-13 | — | — | US | disclosed |
| US-20200323852-A1 | Compounds And Compositions As Protein Kinase Inhibitors | IRM LLC (BM) | 2020-10-15 | — | — | US | disclosed |
| US-10576080-B2 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10568884-B2 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180297985-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2018-10-18 | — | — | US | disclosed |
| US-20180297986-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2018-10-18 | — | — | US | disclosed |
| US-9314464-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2016-04-19 | — | — | US | disclosed |
| EP-2470526-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2014-05-28 | — | — | EP | disclosed |
| EP-2727918-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2014-05-07 | — | — | EP | disclosed |
| US-20130296318-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8501758-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-08-06 | — | — | US | disclosed |
| EP-2470526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-07-04 | — | — | EP | disclosed |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-15 | — | — | US | disclosed |
| WO-2011025927-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200323852-A1 | Compounds And Compositions As Protein Kinase Inhibitors | BRAF, RAF1, ARAF | MAPT 1828/4885HTT 2739/4885TDP1 1617/4885 |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPT 1828/4885HTT 2739/4885TDP1 1617/4885 |
| US-20130296318-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPT 1828/4885HTT 2739/4885TDP1 1617/4885 |
| US-10568884-B2 | Compounds and compositions as protein kinase inhibitors | BRAF, RAF1, ARAF | MAPT 1828/4885HTT 2739/4885TDP1 1617/4885 |
| US-20180297985-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPT 1828/4885HTT 2739/4885TDP1 1617/4885 |
| US-20230116233-A1 | Compounds And Compositions As Protein Kinase Inhibitors | BRAF, RAF1, ARAF | MAPT 1828/4885HTT 2739/4885TDP1 1617/4885 |
| US-20180297986-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPT 1828/4885HTT 2739/4885TDP1 1617/4885 |
| US-10576080-B2 | Compounds and compositions as protein kinase inhibitors | BRAF, RAF1, ARAF | MAPT 1828/4885HTT 2739/4885TDP1 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.